A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma.
Tan TJ, Ang WXG, Wang WW, Chong HS, Tan SH, Cheong R, Chia JW, Syn NL, Shuen WH, Ba R, Kaliaperumal N, Au B, Hopkins R, Li X, Tan AC, Seet AOL, Connolly JE, Arkachaisri T, Chew V, Lajam ABM, Guo D, Chew MZW, Wasser M, Kumar P, Albani S, Toh HC.
Tan TJ, et al.
Nat Commun. 2022 Oct 28;13(1):6453. doi: 10.1038/s41467-022-33834-4.
Nat Commun. 2022.
PMID: 36307410
Free PMC article.
Clinical Trial.